Voloridge Investment Management’s Pelagos Insurance Capital PLGO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$529K Sell
21,716
-92,542
-81% -$2.01M ﹤0.01% 757
2026
Q1
$2.18M Sell
114,258
-146,240
-56% -$2.8M 0.01% 814
2025
Q4
$5.1M Buy
260,498
+185,365
+247% +$3.46M 0.02% 758
2025
Q3
$1.36M Sell
75,133
-224,491
-75% -$3.74M ﹤0.01% 993
2025
Q2
$4.97M Buy
299,624
+192,935
+181% +$3.2M 0.02% 754
2025
Q1
$1.73M Sell
106,689
-71,631
-40% -$1.15M 0.01% 980
2024
Q4
$3.23M Buy
178,320
+165,043
+1,243% +$3.06M 0.01% 869
2024
Q3
$240K Sell
13,277
-93,862
-88% -$1.66M ﹤0.01% 1120
2024
Q2
$1.75M Buy
107,139
+24,646
+30% +$437K 0.01% 971
2024
Q1
$1.61M Buy
+82,493
New +$1.21M 0.01% 895

Other funds holding PLGO

Voloridge Investment Management's PLGO Position: Q2 2026 in Review

Voloridge Investment Management reduced its Pelagos Insurance Capital (PLGO) stake by 81% in Q2 2026, selling an estimated $2.01M and leaving 21,716 shares worth $529K. The position accounts for ﹤0.01% of the portfolio, ranked #757.

Voloridge Investment Management first reported a position in PLGO in Q1 2024 and has held it in 10 quarters since. The position peaked at $5.1M in Q4 2025. 172 funds tracked by Wall St. Rank hold PLGO as of Q2 2026.

  • Voloridge Investment Management held 21,716 shares of Pelagos Insurance Capital worth $529K as of Q2 2026.
  • Voloridge Investment Management sold 92,542 Pelagos Insurance Capital shares in Q2 2026, an estimated $2.01M.
  • Pelagos Insurance Capital made up ﹤0.01% of Voloridge Investment Management's portfolio in Q2 2026, its #757 holding.
  • Voloridge Investment Management first reported a position in Pelagos Insurance Capital in Q1 2024 and has held it in 10 quarters since.
  • Voloridge Investment Management's Pelagos Insurance Capital position peaked at $5.1M in Q4 2025.
  • 172 funds tracked by Wall St. Rank held Pelagos Insurance Capital as of Q2 2026.

Based on Voloridge Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.